5. 進行性核上性麻痺 Progressive supranuclear palsy Clinical trials / Disease details
臨床試験数 : 95 / 薬物数 : 119 - (DrugBank : 40) / 標的遺伝子数 : 65 - 標的パスウェイ数 : 108
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ChiCTR2000041207 | 2021-01-01 | 2020-12-22 | A registered cohort study on progressive supranuclear palsy (PSP) | A registered cohort study on progressive supranuclear palsy (PSP) | progressive supranuclear palsy | Gold Standard:Diagnostic criteria of MDS for progressive supra-nuclear palsy (2017) and the Chinese clinical diagnostic criteria for progressive supra-nuclear palsy (2016).;Index test:The progression of PSP rating scales. Tau protein-related pathological examination (for example, Tau protein content in blood, Tau protein-related detection in cerebrospinal fluid in patients with cognitive impairment, etc.), and brain Tau PET imaging.; | Huashan Hospital, Fudan University | NULL | Recruiting | 40 | 85 | Both | Target condition:100;Difficult condition:0 | China | |
| 2 | ChiCTR2000030512 | 2019-05-13 | 2020-03-05 | Clinical study of [18F]-APN-1607([18F]-PM-PBB3) PET on tau tangles in the brain of progressive supranuclear palsy | Clinical study of [18F]-APN-1607([18F]-PM-PBB3) PET on tau tangles in the brain of progressive supranuclear palsy | progressive supranuclear palsy | Gold Standard:clinical diagnosis of progressive supranuclear palsy the movement disorder society criteria in 2017.(Mov Disord. 2017 Jun;32(6):853-864. doi: 10.1002/mds.26987. Epub 2017 May 3.).;Index test:Standard uptake value ratio of [18F]-APN-1607([18F]-PM-PBB3); | Huashan Hospital, Fudan University | NULL | Recruiting | 45 | 80 | Both | Target condition:26;Difficult condition:0 | China |